Skip to main content

FDA Approvals

Injectafer (Ferric Carboxymaltose Injection) Receives FDA Approval for the Treatment of Iron-Deficiency Anemia

Fetzima Extended-Release Receives FDA Approval for the Treatment of Major Depressive Disorder in Adults

Simponi Aria: A New Intravenous TNF Inhibitor for the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis

Breo Ellipta: A Fixed-Dose Combination Oral Inhaler Receives FDA Approval for Long-Term Maintenance Treatment of COPD

Invokana (Canagliflozin): First-in-Class SGLT2 Inhibitor Approved for the Treatment of Type 2 Diabetes

Nesina, Kazano, and Oseni: Three Alogliptin-Based Agents Approved for the Treatment of Type 2 Diabetes

Tafinlar and Mekinist: Two Oral Targeted Kinase Inhibitors for the Treatment of Patients with Metastatic Melanoma and BRAF Mutations

Lisa A. Raedler, PhD, RPh

Simbrinza (Brinzolamide/Brimonidine Tartrate) Receives FDA Approval for the Treatment of Open-Angle Glaucoma or Ocular Hypertension

Ilaris (Canakinumab) Receives a New Indication for the Treatment of Systemic Juvenile Idiopathic Arthritis

Lisa A. Raedler, PhD, RPh

Xofigo (Radium Ra 223 Dichloride): The First Alpha Particle–Emitting Radioactive Agent for the Treatment of Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases

Lisa A. Raedler, PhD, RPh

Page 20 of 21
Results 191 - 200 of 206